Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.
The intersection of small molecular weight drugs and antibody-based therapeutics is rarely studied in large scale. Both types of agents are currently part of the cancer armamentarium. However, very little is known about how to combine them in optimal ways. Immunotoxins are antibody-toxin gene fusion...
Main Authors: | Antonella Antignani, Lesley Mathews Griner, Rajarshi Guha, Nathan Simon, Matteo Pasetto, Jonathan Keller, Manjie Huang, Evan Angelus, Ira Pastan, Marc Ferrer, David J FitzGerald, Craig J Thomas |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4996465?pdf=render |
Similar Items
-
Immunotoxins: The Role of the Toxin
by: David FitzGerald, et al.
Published: (2013-08-01) -
Targeting Receptors on Cancer Cells
with Protein Toxins
by: Antonella Antignani, et al.
Published: (2020-09-01) -
Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation
by: Ronit Mazor, et al.
Published: (2020-06-01) -
Toxin-Based Targeted Therapy for Malignant Brain Tumors
by: Vidyalakshmi Chandramohan, et al.
Published: (2012-01-01) -
Asthma guidelines: Global to local
by: FitzGerald J
Published: (2009-01-01)